Literature DB >> 22281003

Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis-Ekbom disease).

D Tzonova1, O Larrosa, E Calvo, J J Granizo, A-M Williams, Y de la Llave, D García-Borreguero.   

Abstract

BACKGROUND: It is often assumed that most patients with restless legs syndrome (RLS) only experience symptoms at night. However, previous studies have estimated the prevalence of daytime symptoms to be 10-60%. This study sought to investigate the prevalence and pattern of daytime symptoms in patients with moderate-to-severe RLS.
METHODS: Observational, cross-sectional investigation. A self-administered questionnaire was sent out, on a random basis, to 310 patients with RLS by the Spanish RLS patient support group. Only individuals with a confirmed diagnosis of RLS were included in the final survey.
RESULTS: In total, 224 individuals were included in the survey (response rate 72%). Over 55% of patients reported daytime crises on most (>3) days of the week, and 41% suffered daytime symptoms on a daily basis. These breakthrough crises were characterized by unexpected and sudden symptoms and were frequently precipitated by a reduction in daytime activity. The mean severity of these crises on a visual analogue scale (range 0-10) was 6.8 (standard deviation 2.1), and they had a major impact on quality of life. The prevalence of breakthrough crises was related to duration of illness but not to duration of treatment.
CONCLUSION: This study suggests that breakthrough crises are common in moderate-to-severe RLS and have a negative effect on quality of life. More studies are needed to investigate whether breakthrough crises reflect disease progression or, at least for those patients undergoing dopaminergic treatment, whether they represent an early indication of RLS augmentation.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22281003     DOI: 10.1016/j.sleep.2011.09.015

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  10 in total

Review 1.  Therapeutic Utility of Opioids for Restless Legs Syndrome.

Authors:  Susan E Mackie; John W Winkelman
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546

Review 2.  Long-Term Treatment of Restless Legs Syndrome (RLS): An Approach to Management of Worsening Symptoms, Loss of Efficacy, and Augmentation.

Authors:  Susan Mackie; John W Winkelman
Journal:  CNS Drugs       Date:  2015-05       Impact factor: 5.749

3.  Preface for the 3rd Clinical Update Sleep, 23rd February 2018, Royal College of Physicians, London, UK: year in review.

Authors:  Culadeeban Ratneswaran; Manpreet K Sagoo; Joerg Steier
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

4.  Treatment Options in Intractable Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED).

Authors:  Fabrizio Rinaldi; Andrea Galbiati; Sara Marelli; Luigi Ferini Strambi; Marco Zucconi
Journal:  Curr Treat Options Neurol       Date:  2016-02       Impact factor: 3.598

5.  Assessment of change in restless legs syndrome symptoms during the acute drug-withdrawal period.

Authors:  Allan Wang; Keyana Foster; Patrick Skeba; Kasidet Hiranniramol; Christopher J Earley; Richard P Allen
Journal:  Sleep Med       Date:  2018-08-17       Impact factor: 3.492

Review 6.  Restless legs syndrome-current therapies and management of augmentation.

Authors:  Claudia Trenkwalder; Juliane Winkelmann; Yuichi Inoue; Walter Paulus
Journal:  Nat Rev Neurol       Date:  2015-07-28       Impact factor: 42.937

7.  Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension.

Authors:  Wolfgang H Oertel; Yngve Hallström; Gerda M Saletu-Zyhlarz; Michael Hopp; Björn Bosse; Claudia Trenkwalder
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

8.  Validation of the Multiple Suggested Immobilization Test: A Test for the Assessment of Severity of Restless Legs Syndrome (Willis-Ekbom Disease).

Authors:  Diego Garcia-Borreguero; Ralf Kohnen; Lindsay Boothby; Desislava Tzonova; Oscar Larrosa; Elmar Dunkl
Journal:  Sleep       Date:  2013-07-01       Impact factor: 5.849

9.  Restless Legs Syndrome: Known Knowns and Known Unknowns.

Authors:  Elena Antelmi; Lorenzo Rocchi; Anna Latorre; Daniele Belvisi; Francesca Magrinelli; Kailash P Bhatia; Michele Tinazzi
Journal:  Brain Sci       Date:  2022-01-16

Review 10.  Incidence of Augmentation in Primary Restless Legs Syndrome Patients May Not Be That High: Evidence From A Systematic Review and Meta-Analysis.

Authors:  Guang Jian Liu; Lang Wu; Song Lin Wang; Li Ding; Li Li Xu; Yun Fu Wang; Li Ying Chang
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.